Greatmark Investment Partners’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q2
Sell
-19,798
Closed -$1.69M 138
2021
Q1
$1.69M Sell
19,798
-390
-2% -$35K 0.33% 56
2020
Q4
$1.91M Sell
20,188
-618
-3% -$54K 0.41% 47
2020
Q3
$1.81M Buy
20,806
+48
+0.2% +$4.16K 0.45% 44
2020
Q2
$1.81M Sell
20,758
-334
-2% -$28.8K 0.48% 44
2020
Q1
$1.74M Buy
21,092
+740
+4% +$66K 0.56% 43
2019
Q4
$1.93M Buy
20,352
+1,110
+6% +$99.6K 0.48% 44
2019
Q3
$1.67M Sell
19,242
-635
-3% -$57K 0.46% 45
2019
Q2
$1.81M Sell
19,877
-922
-4% -$78K 0.54% 46
2019
Q1
$1.79M Buy
20,799
+693
+3% +$55.6K 0.57% 44
2018
Q4
$1.55M Buy
20,106
+2,277
+13% +$177K 0.55% 42
2018
Q3
$1.38M Buy
17,829
+3,872
+28% +$286K 0.43% 48
2018
Q2
$945K Buy
13,957
+811
+6% +$56K 0.33% 58
2018
Q1
$952K Buy
13,146
+340
+3% +$25.9K 0.35% 56
2017
Q4
$963K Sell
12,806
-826
-6% -$62.3K 0.35% 56
2017
Q3
$1.05M Buy
13,632
+1,278
+10% +$96.5K 0.4% 53
2017
Q2
$924K Buy
12,354
+530
+4% +$37.6K 0.37% 53
2017
Q1
$787K Buy
11,824
+6,690
+130% +$446K 0.32% 57
2016
Q4
$335K Buy
+5,134
New +$333K 0.14% 75

Other funds holding NVS

Greatmark Investment Partners's NVS Position: Q2 2021 in Review

Greatmark Investment Partners sold out of Novartis (NVS) in Q2 2021, closing a stake of 19,798 shares — an estimated $1.69M sold.

Greatmark Investment Partners first reported a position in NVS in Q4 2016 and held it in 18 quarters. The position peaked at $1.93M in Q4 2019. 1,119 funds tracked by Wall St. Rank hold NVS as of Q2 2021.

  • Greatmark Investment Partners reported no remaining Novartis position as of Q2 2021 after selling out during the quarter.
  • Greatmark Investment Partners sold 19,798 Novartis shares in Q2 2021, an estimated $1.69M.
  • Greatmark Investment Partners first reported a position in Novartis in Q4 2016 and held it in 18 quarters.
  • Greatmark Investment Partners's Novartis position peaked at $1.93M in Q4 2019.
  • 1,119 funds tracked by Wall St. Rank held Novartis as of Q2 2021.

Based on Greatmark Investment Partners's 13F filing for Q2 2021, filed 23 Aug 2021.